Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Guillain–Barré syndrome

826 views

Published on

Published in: Health & Medicine
  • Be the first to comment

Guillain–Barré syndrome

  1. 1. Gullain-Barre syndrome by; Belton Winford
  2. 2. • is an acute polyneuropathy, a disorder affecting the peripheral nervous system. • Ascending paralysis, weakness beginning in the feet and hands and migrating towards the trunk • also can cause cranial nerve dysfunction
  3. 3. Epidemiology • Worldwide, the annual incidence is about 0.6–1.9 occurrences per 100,000 people • Men are one and a half times more likely to be affected than women • the incidence increasees in patients with Hodgkin disease,pregnancy or general surgery
  4. 4. Etiology • autoimmune response -The targets of such immune attack are thought to be gangliosides, compounds naturally present in large quantities in human peripheral nerve tissues - infections by bacterium Campylobacter jejun, cytomegalovirus, influenza virus,
  5. 5. Pathphysiology • focal segmental demyelination with endoneurial monocytic infiltrate
  6. 6. Variants • acute motor axonal neuropathy - motor axonal degeneration with little or no demyelination or imflammation - may follow infections with Campylobacter jejuni or parenteral injection of gangliosides • the Miller-Fisher syndrome - characterized by gait ataxia, areflexia and ophthalmoparesis; papillary abnormalities are sometimes present
  7. 7. • acute motor and sensory axonal neuropathy or neuronopathy • acute autonomic neuropathy or pandysautonomia
  8. 8. Diagnostic criteria • features required for diagnosis - progressive motor weakness of more than 1 limb [ from minimum weakness to +/- ataxia to paralysis - areflexia [usually universal but distal areflexia with difinite hyporeflexia of biceps and knee jerks sufficess if other features consistent]
  9. 9. Clinical features • progression motor weakness peaks at 2wks in 50% , 3wks 80% , 4wks > 90% • relative symmetry • mild sensory symptoms/signs eg mild paresthesias in hands or feets • cranial nerve involvment ; facial weakness , oropharyngeal muscles may be affected • recovery usually 2-4wks after progression stops , may be delayed for months
  10. 10. • autonomic dysfunction [ may flactuate] tachycardia, arrythmias, postural hypotension , HTN, vasomotor symptoms • afebrile at onset of neuritic symptoms • fever, • severe sensory loss with pain • progression >4wks • cessation of progression without recovery • sphincter dysfunction eg; bladder paralysis
  11. 11. CSF findings • protein > 55mg/dl • cells <10 mononuclear leukocytes/ml • variants - no protein rise - 11-50 monocytes/ml
  12. 12. differential diagnosis • acute polyneuropathy • acute polyneuropathy after administration of penicillin • infections affecting the anterior horn ganglion cells • myasthenia gravis • acute myopathies • albumincytologic dissociation of the CSF due to another disease • Acquired immunodeficiency syndrome
  13. 13. Treatment The patient needs to be in a unit where intensive respiratory care is available. Respiratory assistance should be instituted at the first sign of dyspnea (arterial PO2< 70 mmHg) or markedly reduced vital capacity (<12 to 15 mL/kg) • early plasaphaeresis hastens recovery and reduces the residual deficit • immunoglobulins may be helpful in severe cases
  14. 14. Prognosis • recovery may not be complete for several months • 35% of untreated patients have residual weakness and atrophy • reccurance after maximum recovery occours in 2%
  15. 15. THANK YOU

×